Osimertinib as adjuvant therapy in patients with stage IB–IIIA EGFR mutation positive NSCLC after complete tumor resection:

ADAURA

Presented By Roy Herbst at TBD

1 in 3 patients with NSCLC present with resectable disease

Presented By Roy Herbst at TBD

Outcomes in early stage NSCLC need to be improved

Presented By Roy Herbst at TBD

 Slide 4

Presented By Roy Herbst at TBD

 Slide 5

Presented By Roy Herbst at TBD

 Slide 6

Presented By Roy Herbst at TBD

 Slide 7

Presented By Roy Herbst at TBD

 Slide 8

Presented By Roy Herbst at TBD

 Slide 9

Presented By Roy Herbst at TBD

 Slide 10

Presented By Roy Herbst at TBD

 Slide 11

Presented By Roy Herbst at TBD

 Slide 12

Presented By Roy Herbst at TBD

 Slide 13

Presented By Roy Herbst at TBD

 Slide 14

Presented By Roy Herbst at TBD

 Slide 15

Presented By Roy Herbst at TBD

 Slide 16

Presented By Roy Herbst at TBD

 Slide 17

Presented By Roy Herbst at TBD